M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical TechnologyEli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Technology Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash. M&A / DealsRead full story Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026